AbbVie Inc. (ABBV) Stock Analysis
Momentum Cont setup
Healthcare · Drug Manufacturers - General
Sell if holding. At $227.45, A.R:R 0.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: McKesson, Cardinal Health, Cencora; Concentration risk — Supplier: single-source suppliers.
AbbVie develops and commercializes biopharmaceuticals across immunology (Skyrizi, Rinvoq, Humira), neuroscience (Vraylar, Botox Therapeutic), oncology (Imbruvica, Venclexta), and aesthetics (Botox Cosmetic, Juvederm). Skyrizi and Rinvoq together accounted for approximately 42%... Read more
Sell if holding. At $227.45, A.R:R 0.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: McKesson, Cardinal Health, Cencora; Concentration risk — Supplier: single-source suppliers. Chart setup: Trend continuation, RSI 66, MACD bullish. Score 5.3/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 45d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About AbbVie Inc.
About AbbVie Inc.
Skyrizi and Rinvoq each exceeded 10% of AbbVie's total net revenues in 2025, together accounting for approximately 42% of consolidated net revenues. Three AbbVie products — Imbruvica, Vraylar, and Botox — have been selected for Medicare government-set pricing under the Inflation Reduction Act, with effective dates of January 2026, January 2027, and January 2028 respectively. AbbVie's portfolio spans immunology, neuroscience, oncology, aesthetics, and eye care, marketed through dedicated commercial organizations across major global markets.
AbbVie generates revenue through wholesale distributors; McKesson Corporation, Cardinal Health, and Cencora collectively handle substantially all U.S. pharmaceutical product sales, with no individual wholesaler exceeding 43% of 2025 gross U.S. revenues. Outside the U.S., the company sells primarily through wholesalers and distributors, working with centralized national payer systems on reimbursement terms. Immunology products including Skyrizi, Rinvoq, and Humira compete against IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, biosimilars, and other products. In January 2026, AbbVie entered a voluntary agreement with the U.S. government to provide pricing concessions and U.S.-based research and capital investments in exchange for exemptions from tariffs and future pricing mandates for a three-year period. Manufacturing of biologics is complex and may rely on single-source suppliers for certain raw materials, with finding alternative sources potentially requiring significant time and regulatory approvals.
Show full overview
Humira now faces direct biosimilar competition globally, and the 10-K acknowledges that patent expiration is typically followed promptly by substitutes that may significantly reduce sales in a short time. The IRA creates sequential pricing pressure beyond Humira: Imbruvica became subject to Medicare government-set prices in January 2026, Vraylar and Linzess face the same beginning January 2027, and Botox was added for January 2028. The filing warns that more products generating substantial revenues could be selected in future years, which could accelerate revenue erosion prior to expiration of intellectual property protections.
See also: Healthcare · Drug Manufacturers - General
From AbbVie Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-14Recent Developments — AbbVie Inc.
Latest news
- NEWS AbbVie (NYSE:ABBV) Stock Price Down 2.3% - Should You Sell? - MarketBeat — MarketBeat negative
- NEWS AbbVie (ABBV) Stock Jumps On $1.4 Billion North Carolina Campus Announcement - MEXC — MEXC positive
- NEWS AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus - PR Newswire — PR Newswire positive
- NEWS AbbVie Inc. (ABBV) is attracting investor attention: Here is what you should know - MSN — MSN positive
- NEWS Kingswood Wealth Advisors LLC Raises Stock Holdings in AbbVie Inc. $ABBV - MarketBeat — MarketBeat neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductSkyrizi and Rinvoq42%10-K Item 1A: 'Skyrizi and Rinvoq each represented greater than 10% of AbbVie's total net revenues and, in aggregate, these products accounted for approximately 42% of total net revenues in 2025'
- HIGHCustomerMcKesson, Cardinal Health, Cencora10-K Item 1: '(McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States'
- HIGHSuppliersingle-source suppliers10-K Item 1A: 'AbbVie uses raw materials and components in its pharmaceutical and biologic manufacturing processes that may be sourced from single suppliers'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $227.45, A.R:R 0.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: McKesson, Cardinal Health, Cencora; Concentration risk — Supplier: single-source suppliers. Chart setup: Trend continuation, RSI 66, MACD bullish. Prior stop was $217.03. Score 5.3/10, moderate confidence.
Take-profit target: $228.20 (+0.2% upside). Prior stop was $217.03. Stop-loss: $217.03.
Concentration risk — Customer: McKesson, Cardinal Health, Cencora; Concentration risk — Supplier: single-source suppliers; Analyst target reached - limited upside remaining.
AbbVie Inc. trades at a P/E of 111.1 (forward 14.0). TrendMatrix value score: 5.6/10. Verdict: Sell.
40 analysts cover ABBV with a consensus score of 4.0/5. Average price target: $254.
What does AbbVie Inc. do?AbbVie develops and commercializes biopharmaceuticals across immunology (Skyrizi, Rinvoq, Humira), neuroscience...
AbbVie develops and commercializes biopharmaceuticals across immunology (Skyrizi, Rinvoq, Humira), neuroscience (Vraylar, Botox Therapeutic), oncology (Imbruvica, Venclexta), and aesthetics (Botox Cosmetic, Juvederm). Skyrizi and Rinvoq together accounted for approximately 42% of 2025 net revenues; McKesson, Cardinal Health, and Cencora collectively handle substantially all U.S. pharmaceutical product sales.